Black Diamond Therapeutics
Pre-clinicalOur MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. Our efforts are focused on non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Founded
2017
Focus
Small Molecules
About
Our MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. Our efforts are focused on non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Funding History
3Total raised: $306.6M
IPO$201.6MUndisclosedJan 15, 2020
Series A$85MVersant VenturesOct 15, 2018
Seed$20MVersant VenturesJun 15, 2017
Company Info
TypePrivate
Founded2017
LocationCambridge, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile